Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2493 | 28.988372093 | 0.86 | 1.35 | 0.82 | 2319815 | 1.22402589 | CS |
4 | 0.2293 | 26.0568181818 | 0.88 | 1.35 | 0.8 | 983270 | 1.09633722 | CS |
12 | 0.3993 | 56.2394366197 | 0.71 | 1.35 | 0.6354 | 652402 | 0.94757189 | CS |
26 | 0.0793 | 7.69902912621 | 1.03 | 1.35 | 0.63 | 735244 | 0.91749768 | CS |
52 | -1.1407 | -50.6977777778 | 2.25 | 3.1399 | 0.63 | 517919 | 1.18396039 | CS |
156 | -10.7007 | -90.6071126164 | 11.81 | 12.73 | 0.63 | 262355 | 2.42997819 | CS |
260 | -40.9107 | -97.3600666349 | 42.02 | 63.62 | 0.63 | 240079 | 6.32367987 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관